Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Research finding could lead to first effective therapies, vaccines against dengue virus

Research finding could lead to first effective therapies, vaccines against dengue virus

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

American Journal of Respiratory and Critical Care Medicine publishes overview of MERS-CoV outbreak in Korea

American Journal of Respiratory and Critical Care Medicine publishes overview of MERS-CoV outbreak in Korea

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

UC Santa Barbara professor develops novel therapeutic strategy for PKD

UC Santa Barbara professor develops novel therapeutic strategy for PKD

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

Celimmune to provide oral presentation on AMG 714 antibody at 16th International Coeliac Disease Symposium

Celimmune to provide oral presentation on AMG 714 antibody at 16th International Coeliac Disease Symposium

CGRP monoclonal antibodies show promise in treating migraine

CGRP monoclonal antibodies show promise in treating migraine

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Novasep announces launch of BioSC Lab for protein purification

Novasep announces launch of BioSC Lab for protein purification

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

Ixekizumab drug shows quick and extensive improvements in patients with psoriasis

Ixekizumab drug shows quick and extensive improvements in patients with psoriasis

Creative Diagnostics announces launch of antibody generation service based on DNA immunization technology

Creative Diagnostics announces launch of antibody generation service based on DNA immunization technology

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.